alphamab oncology is elected as one of “2020 china top 500 new economy”-凯发vip

english 中文简体 中文繁体

alphamab oncology is elected as one of “2020 china top 500 new economy”

november 30, 2020 08:13 eastern daylight time

on november 28, alphamab oncology is gloriously selected on the list of “2020 china top 500 new economy”. mr. ma weidong, vice president of quality of alphamab oncology, attended the press conference.


the report of the 19th national congress of the communist party of china pointed out that my country's economy has shifted from a stage of high-speed growth to a stage of high-quality development stage, and it is in a period of tackling key problems in transforming the development mode, optimizing the economic structure, and transforming the growth momentum. in order to implement the spirit of the instructions of the party central committee and the state council, further optimize and adjust the economic structure, and improve the quality and efficiency of economic growth, the china enterprises evaluation association organized for the first time the "china top 500 chinese new economy" list, aiming to launch a group of representative and innovative benchmarking enterprises with high standards to promote the development of new economic industries.


with the care and support of government and leaders at all levels, alphamab oncology has achieved breakthrough development in ten years and successfully listed on the main board of the hong kong stock exchange in 2019. in recent years, alphamab oncology has invested more than 1.5 billion yuan in suzhou to successfully build a globally competitive product pipeline based on bispecific antibody, and build a state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards. the world’s first subcutaneous pd-l1 antibody (kn035) which is originally developed by alphamab oncology has been submitted biologic license application in china. the world’s first recombinant humanized pd-l1/ctla-4 bispecific antibody (kn046) and anti-her2 bispecific antibody (kn026) have entered the registration/phase iii clinical trials of multiple indications for single or combination therapies. it is expected to provide patients with more excellent treatment options and address unmet clinical needs.


in the future, alphamab oncology will continue to work hard to use our innovative results to help "healthy china 2030", improve the quality of life of patients, and make greater contributions to the high-quality development of china's economy.


alphamab oncology forward-looking statements

this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.